The state of Arizona currently has 7 active clinical trials seeking participants for Rheumatoid Arthritis research studies. These trials are conducted in various cities, including Phoenix, Tucson, Scottsdale and Mesa.
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Recruiting
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is doubl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 253431, Flagstaff, Arizona +5 locations
Conditions: Rheumatoid Arthritis
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
Recruiting
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans. Increasing dose levels will be given after the safety at lower dose levels is shown.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/21/2024
Locations: Mayo Clinic, Scottsdale, Arizona
Conditions: Rheumatoid Arthritis
RA-PRO PRAGMATIC TRIAL
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: SunValley Arthritis Center, Ltd, Peoria, Arizona +1 locations
Conditions: Rheumatoid Arthritis
A Study of Baricitinib in Participants With Rheumatoid Arthritis
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: Arizona Arthritis & Rheumatology Associates, Flagstaff, Arizona +8 locations
Conditions: Rheumatoid Arthritis
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
Recruiting
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with moderate to severe rheumatoid arthritis who have failed prior therapies. Participants will be given imvotamab or placebo through a vein (i.e., intravenously). A placebo is a look-alike substance that contains no active drug
Gender:
All
Ages:
18 years and above
Trial Updated:
01/16/2024
Locations: Arizona Arthritis & Rheumatology Research, PLLC, Flagstaff, Arizona +1 locations
Conditions: Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
COVID-19 VaccinE Response in Rheumatology Patients
Recruiting
The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy and safety of a mRNA COVID-19 vaccine supplemental dose (booster) in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. The investigators propose to recruit up to 1000- patients with autoimmune conditions who have a completed 2-dose regime of mRNA COVID-19 vaccine (>28 days prio... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/06/2023
Locations: Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona
Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (RENOIR)
Recruiting
RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/11/2023
Locations: Anaptys Bio Investigative Site 10-132, Flagstaff, Arizona +3 locations
Conditions: Rheumatoid Arthritis